The peer-review journal Lancet recently published a study that found a vaccine candidate targeting the Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.
The vaccine known as cAd3-Marburg vaccine, developed by researchers at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), could become an essential tool if approved to respond to future Marburg virus outbreaks.
Read More
